Anonymized prior work
Cell therapy
Early investment and partnership reviews of autologous and allogeneic cell programs, including platform-plus-pipeline structures where the thesis mixed product claims with manufacturing and control-strategy readiness.
Decision pressure
Term-sheet timing forced a sharp cut between what was demonstrated in limited clinical/process packages versus what still depended on unproven scale, release, or comparability assumptions.
Boundary
Did not substitute for formal CMC, regulatory, or clinical-statistical opinions; flagged when those were required.
Claims usually tested
- Whether potency and product identity claims were solid enough for the proposed next study
- Whether CMC / process control risk would consume the raise before a claim-resolving readout
- Whether comparator and failed-analogue programs actually supported the differentiation story
Example decision triggers
- Potency assay or release strategy not yet tied to the clinical claim
- Comparability after process change left as narrative rather than a plan
- Use of proceeds not mapped to the manufacturing gates that have to clear